Drug research

Eribulin

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Halaven

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559	ALX Oncology Inc.	Phase 2	Recruiting	2027-12Estimated
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429	Jazz Pharmaceuticals	Phase 3	Recruiting	2028-04-28Estimated
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)NCT06263231	INTS	Phase 3	Recruiting	2027-12Estimated

ALX Oncology Inc.RecruitingPrimary completion: 2027-12 · Estimated

Trial details

Jazz PharmaceuticalsRecruitingPrimary completion: 2028-04-28 · Estimated

Trial details

INTSRecruitingPrimary completion: 2027-12 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.